|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.☆** | | | |
|  | **Remdesivir** | **Placebo** | **Total** |
| **Characteristic** | **(N=279)** | **(N=283)** | **(N=562)** |
| Age—yr | 49.7±15 | 50.6±15 | 50.2±15 |
| Age category — no. (%) | | | |
| ≥60 yr | 78 (28) | 80 (28.3) | 158 (28.1) |
| <18 yr | 2 (0.7) | 1 (0.4) | 3 (0.5) |
| Female sex — no. (%) | 128 (45.9) | 143 (50.5) | 271 (48.2) |
| Residence in the United States — no. (%)† | 263 (94.3) | 267 (94.3) | 530 (94.3) |
| Race or ethnic group — no. (%) | | | |
| White | 216 (77.4) | 218 (77) | 434 (77.2) |
| Black | 21 (7.5) | 26 (9.2) | 47 (8.4) |
| American Indian or Alaska Native | 19 (6.8) | 19 (6.7) | 38 (6.8) |
| Asian, Native Hawaiian, or Pacific Islander | 7 (2.5) | 5 (1.8) | 12 (2.1) |
| Hispanic or Latinx | 117 (41.9) | 110 (38.9) | 227 (40.4) |
| Other | 5 (1.8) | 1 (0.4) | 6 (1.1) |
| Body-mass index | 31±6.8 | 30.6±5.9 | 30.8±6.4 |
| Coexisting conditions — no. (%) | | | |
| Diabetes mellitus | 171 (61.3) | 173 (61.1) | 344 (61.2) |
| Obesity | 144 (51.6) | 143 (50.5) | 287 (51.1) |
| Hypertension | 133 (47.7) | 112 (39.6) | 245 (43.6) |
| Chronic lung disease | 62 (22.2) | 61 (21.6) | 123 (21.9) |
| Current cancer | 9 (3.2) | 13 (4.6) | 22 (3.9) |
| Cardiovascular or cerebrovascular disease | 13 (4.7) | 25 (8.8) | 38 (6.8) |
| Immune compromise | 14 (5) | 9 (3.2) | 23 (4.1) |
| Chronic kidney disease, mild or moderate | 7 (2.5) | 10 (3.5) | 17 (3) |
| Chronic liver disease | 2 (0.7) | 2 (0.7) | 4 (0.7) |
| Residence in skilled nursing facility — no. (%) | 8 (2.9) | 8 (2.8) | 16 (2.8) |
| Median duration of symptoms before first infusion (IQR) — days | 5 (3-6) | 5 (4-6) | 5 (3-6) |
| Median time since RT-PCR confirmation of SARS-CoV-2 (IQR) — days | 2 (1-3) | 3 (1-4) | 2 (1-3) |
| Mean SARS-CoV-2 RNA nasopharyngeal viral load — log10 copies/ml‡ | 6.4±1.9 | 6.4±1.9 | 6.4±1.9 |
| ☆Plus–minus values are means ±SD. IQR denotes interquartile range, RT-PCR reverse transcriptase–polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2. | | | |
| †Race and ethnic group were reported by the patients. Patients could have had more than one race or ethnic group. | | | |
| ‡Data are shown for the virologic analysis set, which is defined in the statistical analysis plan (available with the protocol at NEJM.org): 215 of 279 patients (77.1%) in the remdesivir group and 213 of 283 patients (75.3%) in the placebo group. | | | |